TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression

Area of Science:

• Cell Biology
• Immunology
• Bone Biology

Background:

• Osteoclasts are crucial for bone remodeling, and their dysregulation contributes to diseases like osteoporosis and rheumatoid arthritis (RA).
• Transforming growth factor beta1 (TGFβ1) is a multifunctional cytokine involved in bone remodeling, but its precise role in osteoclastogenesis is debated.
• Understanding TGFβ1's effects on human osteoclast formation is vital for developing targeted therapies.

Purpose of the Study:

• To investigate the effect of TGFβ1 on human osteoclast generation induced by receptor activator of nuclear factor (NF)-κB ligand (RANKL).
• To elucidate the molecular mechanisms by which TGFβ1 influences osteoclast differentiation.

Main Methods:

• Human peripheral blood monocytes were cultured with M-CSF or RANKL, with or without TGFβ1.
• Osteoclast differentiation was assessed by TRAP staining and bone resorption assays.
• Gene and protein expression of NFATc1, NF-κB signaling, and p65 nuclear translocation were analyzed using RT-PCR, Western blotting, luciferase assays, and immunofluorescence.

Main Results:

• TGFβ1 significantly suppressed RANKL-induced human osteoclast development and bone resorption.
• TGFβ1 reduced the expression of NFATc1, a master regulator of osteoclast differentiation.
• TGFβ1 inhibited NFATc1 promoter activity by blocking RANKL-induced nuclear translocation of NF-κB p65.

Conclusions:

• TGFβ1 negatively regulates human osteoclastogenesis induced by RANKL.
• The mechanism involves the downregulation of NFATc1 via inhibition of NF-κB p65 nuclear translocation.
• TGFβ1 emerges as a potential therapeutic target for managing bone loss in RA and other inflammatory bone diseases.